Form 4: Enliven Therapeutics' Chief Scientific Officer Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, sold shares of common stock on August 29, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On August 29, 2024, Joseph P. Lyssikatos, the Chief Scientific Officer of Enliven Therapeutics, sold 11,950 shares of common stock at a weighted average price of $22.4843 per share.
- An additional 50 shares were sold at $23.08 per share.
- These sales were executed under a Rule 10b5-1 trading plan adopted on June 26, 2023.
- Following the transactions, Lyssikatos directly owns no shares but indirectly owns 1,077,936 shares through The Lyssikatos Revocable Trust 12/15/2011, for which he serves as trustee.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating insider trading activity. The sentiment is neutral as it simply reports transactions without expressing any opinion or outlook.
Industry Context
Sales by company insiders are a common occurrence, and the use of 10b5-1 trading plans allows insiders to sell shares over a period of time while avoiding concerns about trading on non-public information. Investors often monitor insider transactions for signals about a company's prospects, but sales under a 10b5-1 plan are generally viewed as less informative than discretionary trades.
Stakeholder Impact
- The sale of shares by a key executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 trading plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 12/15/2011 | Date of The Lyssikatos Revocable Trust |
| 06/26/2023 | Date the Rule 10b5-1 trading plan was adopted |
| 08/29/2024 | Date of the reported transactions (share sales) |
| 09/03/2024 | Date of the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.